UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 648

Sortiert nach

Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia

Investigational new drugs, 2017-10, Vol.35 (5), p.556-565

2017

Link zum Volltext

Verfügbarkeit prüfen

Discovery of N-{2-Methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}-N′-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazine-2,4-diamine (ASP3026), a Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor

Chemical and Pharmaceutical Bulletin, 2018/03/01, Vol.66(3), pp.251-262

2018

Link zum Volltext

Verfügbarkeit prüfen

Masticatory performance and other oral functions in community-dwelling elderly patients without posterior occlusal support by natural teeth

Journal of Oral Science, 2021, Vol.63(4), pp.330-333

2021

Link zum Volltext

Verfügbarkeit prüfen

Relationship between Maximum Tongue Pressure Value and Age, Occlusal Status, or Body Mass Index among the Community-Dwelling Elderly

Medicina (Kaunas, Lithuania), 2020-11, Vol.56 (11), p.623

2020

Link zum Volltext

Verfügbarkeit prüfen

The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice

Molecular cancer therapeutics, 2014-02, Vol.13 (2), p.329-340

2014

Link zum Volltext

Verfügbarkeit prüfen

Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin αv‐mediated ADAM activity in hepatocellular carcinoma: A novel functional target for gefitinib

Cancer science, 2006-02, Vol.97 (2), p.155-162

2006

Link zum Volltext

Verfügbarkeit prüfen

Heregulin‐induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells

International journal of cancer, 2008-07, Vol.123 (2), p.340-347

2008

Link zum Volltext

Verfügbarkeit prüfen

Selective M3 Muscarinic Receptor Antagonist Inhibits Small-Cell Lung Carcinoma Growth in a Mouse Orthotopic Xenograft Model

Journal of Pharmacological Sciences, 2011, Vol.116(1), pp.81-88

2011

Link zum Volltext

Verfügbarkeit prüfen

Molecular Mechanism of Solvent-Induced Crystallization of Syndiotactic Polystyrene Glass. 1. Time-Resolved Measurements of Infrared/Raman Spectra and X-ray Diffraction

Macromolecules, 2001-01, Vol.34 (2), p.310-315

2001

Link zum Volltext

Verfügbarkeit prüfen

An N-terminal Segment of the Active Component of the Bacterial Genotoxin Cytolethal Distending Toxin B (CDTB) Directs CDTB into the Nucleus

The Journal of biological chemistry, 2003-12, Vol.278 (50), p.50671-50681

2003

Link zum Volltext

Verfügbarkeit prüfen

Plasminogen deficiency attenuates postnatal erythropoiesis in male C57BL/6 mice through decreased activity of the LH-testosterone axis

Experimental hematology, 2012-02, Vol.40 (2), p.143-154

2012

Link zum Volltext

Verfügbarkeit prüfen

Biogenesis of the Actinobacillus actinomycetemcomitans Cytolethal Distending Toxin Holotoxin

Infection and Immunity, 2006-06, Vol.74 (6), p.3480-3487

2006

Link zum Volltext

Verfügbarkeit prüfen

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo

Molecular cancer therapeutics, 2010-07, Vol.9 (7), p.1956-1967

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract 866: ASP3026, a selective ALK inhibitor, induces tumor regression in a crizotinib-refractory model and prolongs survival in an intrapleurally xenograft model

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.866-866

2012

Link zum Volltext

Verfügbarkeit prüfen

Squamous cell carcinoma in the renal pelvis of a horseshoe kidney

International journal of urology, 2004-09, Vol.11 (9), p.782-784

2004

Link zum Volltext

Verfügbarkeit prüfen

Abstract A227: Antitumor activities of ASP3026 against EML4-ALK-dependent tumor models

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.A227-A227

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2821: Anti-tumor activity of ASP3026, – A novel and selective ALK inhibitor

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.2821-2821

2011

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma

Cancer science, 2023-04, Vol.114 (4), p.1606-1615

2023

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of claudin 18.2 (CLDN18.2) and the association of biomarkers with clinical activity in patients with gastric or gastroesophageal adenocarcinoma (G/GEJa) treated with zolbetuximab

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.466-466

2023

Link zum Volltext

Verfügbarkeit prüfen

Midwifery scale to support shared decision‐making for unplanned pregnancies: A cross‐sectional study

Nursing & health sciences, 2022-03, Vol.24 (1), p.17-33

2022

Link zum Volltext

Verfügbarkeit prüfen

Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells

Oncotarget, 2019-10, Vol.10 (58), p.6111-6123

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 trial of zolbetuximab in Japanese patients with CLDN18 .2+ gastric or gastroesophageal junction adenocarcinoma

Cancer science, 2023-04, Vol.114 (4), p.1606-1615

2023

Link zum Volltext

Verfügbarkeit prüfen

Shared decision‐making for women facing an unplanned pregnancy: A qualitative study

Nursing & health sciences, 2020-12, Vol.22 (4), p.1186-1196

2020

Link zum Volltext

Verfügbarkeit prüfen

Clinical pharmacology profile of the claudin 18.2 antibody zolbetuximab

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.316-316

2024

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of gilteritinib in combination with chemotherapy in preclinical models of FLT3-ITD + acute myeloid leukemia

Oncotarget, 2019-04, Vol.10 (26), p.2530-2545

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 648

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(527)
Mit Volltextzugriff
(591)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(389)
Life Sciences & Biomedicine
(312)
Humans
(259)
Female
(175)
Male
(158)
Middle Aged
(109)
Aged
(93)
Adult
(66)
Biological And Medical Sciences
(56)
Physical Sciences
(56)
Animals
(54)
Oncology
(36)
Dentistry
(35)
Medicine
(34)
Science & Technology - Other Topics
(34)
Aged, 80 And Over
(33)
General Medicine
(33)
Japan
(33)
Multidisciplinary Sciences
(32)
Chemistry
(31)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia

Discovery of N-{2-Methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}-N′-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazine-2,4-diamine (ASP3026), a Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor

Masticatory performance and other oral functions in community-dwelling elderly patients without posterior occlusal support by natural teeth

Relationship between Maximum Tongue Pressure Value and Age, Occlusal Status, or Body Mass Index among the Community-Dwelling Elderly

The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice

Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin αv‐mediated ADAM activity in hepatocellular carcinoma: A novel functional target for gefitinib

Heregulin‐induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells

Selective M3 Muscarinic Receptor Antagonist Inhibits Small-Cell Lung Carcinoma Growth in a Mouse Orthotopic Xenograft Model

Molecular Mechanism of Solvent-Induced Crystallization of Syndiotactic Polystyrene Glass. 1. Time-Resolved Measurements of Infrared/Raman Spectra and X-ray Diffraction

An N-terminal Segment of the Active Component of the Bacterial Genotoxin Cytolethal Distending Toxin B (CDTB) Directs CDTB into the Nucleus

Plasminogen deficiency attenuates postnatal erythropoiesis in male C57BL/6 mice through decreased activity of the LH-testosterone axis

Biogenesis of the Actinobacillus actinomycetemcomitans Cytolethal Distending Toxin Holotoxin

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo

Abstract 866: ASP3026, a selective ALK inhibitor, induces tumor regression in a crizotinib-refractory model and prolongs survival in an intrapleurally xenograft model

Squamous cell carcinoma in the renal pelvis of a horseshoe kidney

Abstract A227: Antitumor activities of ASP3026 against EML4-ALK-dependent tumor models

Abstract 2821: Anti-tumor activity of ASP3026, – A novel and selective ALK inhibitor

Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma

Prevalence of claudin 18.2 (CLDN18.2) and the association of biomarkers with clinical activity in patients with gastric or gastroesophageal adenocarcinoma (G/GEJa) treated with zolbetuximab

Midwifery scale to support shared decision‐making for unplanned pregnancies: A cross‐sectional study

Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells

Phase 1 trial of zolbetuximab in Japanese patients with CLDN18 .2+ gastric or gastroesophageal junction adenocarcinoma

Shared decision‐making for women facing an unplanned pregnancy: A qualitative study

Clinical pharmacology profile of the claudin 18.2 antibody zolbetuximab

Evaluation of gilteritinib in combination with chemotherapy in preclinical models of FLT3-ITD + acute myeloid leukemia

Suchergebnisse filtern